2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Debu Tripathy, MD, professor of medicine and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment de-escalation in HER2-positive breast cancer.
Patients with clinical stage I HER2-positive breast cancer may be eligible for de-escalated dosing of weekly paclitaxel and trastuzumab (Herceptin), says Tripathy.
Prior to de-escalation, patients will typically undergo up-front surgery to confirm that their disease is not being upstaged, says Tripathy.
If the patient has confirmed early-stage disease, or their tumor is under 3 cm, therapy de-escalation can be considered per data from the phase 2 APT trial, explains Tripathy.
The field is currently awaiting the randomized data from the phase 2 ATEMPT trial to determine whether ado-trastuzumab emtansine (T-DM1; Kadcyla) could be de-escalated, Tripathy concludes.
Related Content: